Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
In light of evidence of non-compliance to oral therapies in breast cancer, how do you monitor patient adherence to therapy in your practice?
Related Questions
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
Would you give KEYNOTE 522 in combination with trastuzumab/pertuzumab neoadjuvantly for multifocal disease?
Are you comfortable combining palliative radiotherapy with Truqap (capivasertib)/ fulvestrant?
For which patients, if any, do you typically order additional imaging workup for staging in early-stage breast cancer?
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?
What would you recommend regarding IVF in a patient with DCIS on tamoxifen dealing with infertility?”
For Her2+ Stage I T1cN0 patients where neoadjuvant therapy is desired to select out patients for post-operative TDM1, is it reasonable to de-escalate neoadjuvant therapy to THP as opposed to TCHP?
What is your treatment approach in a patient with cT2 ER+HER2+ who refuses neoadjuvant chemotherapy?
